and the important bleeding and warfarin safety concern versus Dihexas unproven HGF/c-Met synaptogenesis, the fosgonimeton LIFT-AD Phase 3 failure and the pro-proliferative c-Met concern
Yes, we deliver securely to research facilities across all Australian states and territories, including metropolitan and regional areas
Glycemia reduction in type 2 diabetes - glycemic outcomes
Incretin-based therapy of metabolic disease Abstract Incretin-based therapy of metabolic disease Recent studies show that incretin hormone analogues effectively control blood glucose while producing major weight losses and reducing the risk of all-cause mortality, myocardial infarction, stroke and kidney function impairment
Therefore, diagnosis, monitoring, frequency, severity and assessment of the prognosis for disease progression should be assessed before management decisions